PSY33 Clinical and Economic Analysis of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura in Context of Russian Health Care System  by Vorobyev, P.A. et al.
rived from the 3 phase III clinical trials of tapentadol PR in osteoarthritis and lower
back pain and published literature. Switch rates to 2nd line therapies and co-
medication costs were provided by the National Centre of Pharmacoeconomics
based on the GMS database analysis. Costs of physician visits were obtained by
applying local costs to the number of physician visits in each therapy line obtained
from a retrospective analysis of the UK THIN database of GP patient records. One-
way deterministic and probabilistic sensitivity analyses were undertaken to assess
the impact of parameter uncertainty. RESULTS: Mean annual total costs per pa-
tient from GMS Scheme perspective amount to 4,367€ for tapentadol vs. 4,381€ for
oxycodone. Tapentadol generates 0.6316 QALYs compared to 0.6122 QALYs for
oxycodone, resulting in tapentadol being a dominant treatment. For DP/LTI
Scheme, tapentadol had an ICER of 1,662 €/QALY gained. Results were robust in a
broad range of sensitivity analyses. Probability that tapentadol is cost-effective vs.
oxycodone at threshold of 20,000 €/QALY gained exceeded 95%. CONCLUSIONS:
Compared to oxycodone CR, the most commonly used oral drug for chronic severe
non-cancer pain in Ireland, tapentadol PR appears to be a highly cost-effective
treatment option.
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OBJECTIVES:To assess the cost-effectiveness of tapentadol PR compared to opioids
(morphine, oxycodone, transdermal buprenorphine [TDB] and transdermal fenta-
nyl [TDF]) for the treatment of severe chronic non-cancer pain from the societal
perspective in Portugal. METHODS: A one year Markov transition state model with
monthly cycles was built. Four health states were defined: ‘no withdrawal and no
adverse events treated’, ’occurrence of adverse events (AEs) with need for medical
treatment’, ’withdrawal due to AEs’, and ‘withdrawal due to lack of efficacy’. If
patients did not adequately respond to treatment or withdraw, switching to alter-
native second line opioid (morphine, hydromorphone, TDB or TDF) was consid-
ered. Third line therapy was the absorption state. Data regarding efficacy, tolera-
bility and utility values (EQ-5D) were derived from clinical trials and published
literature. Switch rates to subsequent opioid therapies and resource consumption
were estimated by clinical experts. Costs were calculated from the societal per-
spective. Direct costs were calculated based on official Portuguese prices/tariffs,
indirect costs derived from the National Health Survey. One-way and probabilistic
sensitivity analyses were conducted. RESULTS:Mean annual total costs per patient
amounted to 3793 € for morphine, 3,804€ for TDF, 3891 € for TDB, 3964 € for oxy-
codone, and 4117 € for tapentadol. Total QALYs generated were 0.6102 (morphine),
0.6062 (TDF), 0.6026 (TDB), 0.6096 (oxycodone), and 0.6287 (tapentadol). The result-
ing ICERs (€/QALY gained) for tapentadol yield 7,995 versus oxycodone, 8,685 versus
TDB, 13,943 versus TDF, and 17,547 versus morphine. Varying costs, probabilities,
and utilities by 50%, 10%, and 10%, respectively, resulted in an ICER range
from tapentadol being dominant (vs. oxycodone) to 26,000 €/QALY gained (vs.
morphine). CONCLUSIONS: To improve pain relief and quality of life in patients
with severe chronic pain tapentadol appears to be the favourable and cost-effective
treatment option from the societal perspective in Portugal.
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OBJECTIVES: The emergence of new drugs for the treatment of patients with
chronic idiopathic thrombocytopenic purpura (ITP), stimulates the proliferation of
megakaryocyte germ (eltrombopag), stresses the need to conduct a comparative
analysis in their cost-effectiveness, compared with other modern treatment
options. METHODS: Markov modeling was used. Markov model, developed by
GlaxoSmithKline, was adapted to the context of Russian health care system to
assess cost-utility and cost-effectiveness of eltrombopag and romiplostim for
treatment of chronic ITP in patients, for whom splenectomy is contradicted. El-
trombopag and romiplostim were used as first-line options. The simulation was
performed taking into account the time perspective for 2 years, 10 and 20 years.
Data about diagnosis and treatment of ITP in “real world” settings was collected by
interviewing 5 expert-hematologists with expertise in the treatment of chronic ITP,
working in different health facilities in Russia. Only direct medical costs were
calculated. RESULTS: Cost-effectiveness ratio for criterion “additional years of life”
after 2 years of onset was $27,703 for eltrombopag and $31,988 for romiplastim,
after 10 years of onset – $21,758 and $24,700 respectively, after 20 years of onset –
$17,257 and $19,577 respectively. Cost of QALY after 2 years of onset was $39,000 for
eltrombopag and $45,530 for romiplastim, after 10 years of onset – $35,108 and
$40,218 respectively, after 20 years of onset – $32 527 and $37,204 respectively.
CONCLUSIONS: Eltrombopag is cost-effective compared with romiplostim as a
first-line therapy in treatment of chronic idiopathic thrombocytopenic purpura in
patients, for whom splenectomy is contradicted.
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OBJECTIVES: To conduct an economic evaluation comparing, ferinject (Ferric Car-
boxymaltose) with Venofer (iron sucrose), iron sucrose similars (ISS-generic forms
of iron sucrose) and Cosmofer (low molecular weight-LMW iron dextran) in the
management of anaemia patients in Greece.METHODS:A cost-minimization anal-
ysis, from National Health System (NHS) perspective, was conducted since there
are no clear data indicating that one of these regimens is superior to the others in
terms of efficacy. Because iron could be administered either to inpatients (i.e.,
surgical patients or patients hospitalized due to a disease related to chronic or
acute blood loss) or to outpatients (i.e. non-dialysis chronic kidney disease patients
etc), the economic evaluation was undertaken for these two large categories of
patients, separately. Total cost related to each treatment includes the cost of drugs,
the cost of disposables for each infusion, the monitoring cost during infusion (sal-
aries of personnel), the cost for management of adverse events, the cost of visits,
the productivity loss, and the travelling cost of patients. A supplementary budget
impact analysis was also conducted. RESULTS: The mean total (direct) cost of
therapy with Ferric Carboxymaltose was €216.32, in the iron sucrose arm the cost
was €296.34, in the LMW iron dextran arm was €251.12, while in the ISS the cost was
estimated at €324.47 for inpatients. In the case of outpatients the cost of ferric
carboxymaltose was €152.66, the cost of iron sucrose was €285.10, the cost of LMW
iron dextran was €459.88 and the cost of ISS was estimated at €313.13. Various
sensitivity analyses showed that the main results were robust, reaching a statisti-
cal significant difference in 95% level of significance. CONCLUSIONS: Ferric Car-
boxymaltose represents a cost-saving option compared with other alternative
therapies used in the management of anaemia in the National Health Service of
Greece.
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OBJECTIVES: To conduct an economic evaluation for End Stage Renal Disease
(ESRD) diabetic and non diabetic patients treated with Darbepoetin alfa, Epoetin
alfa, Epoetin beta and Epoetin Beta (Methoxy polyetylene Glycol). METHODS: A
cost-minimization analysis was conducted since there are no clear data indicating
differences in terms of efficacy. A probabilistic Markov model was constructed to
simulate during a 20-year time span the progress of patients through four health
states: “dialysis”, “transplantation”, “dialysis after graft failure” and “death”. The
dose required to maintain the desirable Hb level (10 – 12 g/dL) was obtained from
the literature alongside transition probabilities for the baseline cohort (mean age
65, diabetics 54%). Costs were estimated from the perspective of the healthcare
system and reflect the drug administration, the monitoring of patients, transplan-
tations and other resources consumed by patients valued at €2011. A 3.5% discount
rate was used for outcomes. RESULTS: The mean survival (common for all com-
parators) expressed in terms of QALY’s was 2.16 (95%Uncertainty Interval (UI):
2.11-2.21) overall, and 2.23 (95%UI: 2.18-2.29) and 2.10 (95%UI: 2.05-2.14) for patients
without and with diabetes, respectively. The mean total treatment cost for patients
on Darbepoetin alfa was 11,505 (95%UI: €11,322-€11,680) for the entire population,
€11,103 (95%UI: €10,906-€11,299) for diabetic and €11,976 (95%UI: €11,739-€12,197)
for non-diabetic patients. The mean cost of patients on Epoetin alfa was €15,340
(95%UI: €15,118-€15,554), €14,720 (95%UI: €14,466-€14,976), and €16,068 (95%UI:
€15,760-€16,343) respectively. The cost of Epoetin beta was €15,038 (95%UI: €14,783-
€15,292), €14,435 (95%UI: €14,160-€14,707) and €15,746 (95%UI: €15,434-€16,063) re-
spectively. Finally, for patients on Epoetin Beta (Methoxy polyetylene Glycol), it was
€12,057 (95%UI: €11,868-€12,238), €11,624 (95%UI: €11,416-€11,823) and €12,566
(95%UI: €12,320-€12,796) respectively. CONCLUSIONS:Darbepoetin alfa (AranespÒ)
may represent a cost saving option, compared to other alternative therapies used
in the management of ESRD patients in the National Health Service of Greece.
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OBJECTIVES: Obesity represents a considerable and increasing health problem.
The objective of this research was to assess the clinical and cost-effectiveness of
orlistat in overweight and obese patients in primary care. METHODS: A cohort
simulation model was built in Simul8 to explore the potential benefits of treatment
with orlistat compared with standard care. The model used a lifetime horizon to
estimate the incremental cost per quality adjusted life-year (QALY) gained. Clinical
effectiveness was modelled using the results of a mixed treatment comparison.
Longitudinal analyses of the General Practice Research Database (n100,000) were
used to derive BMI related estimates for times to death, primary myocardial infarc-
tion or stroke, onset of type 2 diabetes, and to estimate the natural history of body
mass index (BMI) in people who are obese. Annual probabilities of subsequent
cardiovascular events were estimated using data from the Nottingham Heart At-
tack register and South London Stroke register. Health related quality of life values
were modelled using a relationship between BMI and EQ-5D data controlling for age
an comorbidities. Current event and post-event health states were used to incor-
porate changes in health related quality of life and costs. RESULTS: Deterministic
analysis gave a cost per QALY gained (versus placebo) of £1,665, although this figure
is sensitive to the baseline BMI, due to the strong correlation of BMI and the risk of
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